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mental cost savings, $3,780-$5,518). CONCLUSIONS: Comorbidity improvement
and resolution in CD can be achieved with BC, which confers a commensurate cost
savings to the health care payer.
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OBJECTIVES: Non-adherence to insulin therapy in patients with type 2 diabetes
presents a serious challenge. Potential explanations for non adherence may in-
clude aversion to insulin self-injection and fear of hypoglycemic events. In clinical
trails, insulin analogs have shown to reduce the risk of hypoglycemic events versus
human insulins, and a recent review suggests that insulin delivered via a pen
device may result in greater adherence versus vial and syringe. This study was
conducted to compare the adherence rates of patients initiating basal insulin ther-
apy with insulin detemir (IDet) FlexPen® versus those initiating basal insulin ther-
apy with NPH via vial and syringe. METHODS: Data were gathered from a large US
national payer retrospective claims database, and included only patients with type
2 diabetes that initiated basal insulin therapy with either IDet FlexPen® or NPH in
vials. Patients with claims for any other type of insulin, other than the index insulin
formulations during the 12-month observation period were excluded. Patients
were defined as being adherent to therapy if they had a medication possession
ration (MPR) of at least 0.80 in the 12-month follow up period. RESULTS: The IDet
FlexPen® cohort (n1082) and the NPH vial cohort (n794) were of similar age
(54.06 vs. 53.13, p0.134); however, the IDet FlexPen® cohort had a lower propor-
tion of female patients (44% vs. 55%, p0.001) and fewer patients without a history
of pre-index OADs (9% vs 45%, p0.001), than the NPH vial cohort. After controlling
for important confounders, patients initiating insulin therapy with IDet FlexPen®
were 39% more likely to achieve an MPR of 0.80 or greater versus patients initiating
insulin therapy with NPH vial (95% CI: 1.04-1.85). CONCLUSIONS: These results
suggest that adherence may be improved for patients initiating basal insulin ther-
apy with IDet in the FlexPen® versus NPH in a vial.
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OBJECTIVES: To identify studies examining adherence with oral diabetes mellitus
(DM) medication and the potential association between adherence rates and gly-
cemic control among Brazilian patients. METHODS: A systematic literature search
was performed by two independent reviewers using MEDLINE via Pubmed and
LILACS databases (until May 2011) without limits for time or language. Specific
filters to identify studies assessing Brazilian population were not used in the search
strategy and this assessment was conducted by reviewers. Publications were in-
cluded only if adequate documentation of adherence and population could be
abstracted (adherence outcomes, thresholds used, and characteristics of the
populations). RESULTS: The search strategy identified 289 records (Pubmed174
and LILACS115), from which only 2 cross-sectional studies met the eligibility
criteria and were included in the systematic review. The most recent study (Araujo
2010) was conducted in 2007 and evaluated 79 DM patients using the 4-item
Morisky-Green Test. Gimenes 2006 (n31) was designed to investigate if DM pa-
tients have proper knowledge of their prescription and assessed adherence
through self-reported patient compliance with medication schedule. Araujo 2010
found that 54.4% of DM patients were considered non-compliant according to the
Morisky-Green Test. Taking medication in the wrong schedule and skipping doses
were referred by 54.5% and 34% of patients, respectively. Gimenes 2006 observed
that 48.4% of patients reported taking medication in the wrong schedule and 71% of
them were classified as having unsatisfactory knowledge about their prescription.
Studies examining the association between adherence and glycemic control were
not found. CONCLUSIONS: This review reinforced the lack of adherence data for
Brazilian DM population, but the included studies confirmed that a significant
group of DM patients were poor compliers with treatment, although their findings
should be interpreted with some concerning given the small sample size and ex-
planatory nature.
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OBJECTIVES: To evaluate the patient’s adherence to diabetic medications and the
association between medication adherence and diabetic control outcome.
METHODS: A cross-sectional, investigational study using a convenient sampling
method for data collection was employed. A cohort of 540 diabetic patients attend-
ing diabetes clinic of Hospital Pulau Pinang, Malaysia was identified. A previously
validated Malaysian version of Morisky Medication Adherence Scale (MMAS) was
used for the assessment of medication adherence. Medical records were reviewed
for Hemoglobin A1C (HbA1C) levels and other diabetes related information.
RESULTS: Only 505 patients were included in the final analysis. The mean age of
the patients was 58.16 years (SD9.16), with 50.7% males and the mean diabetes
duration was 9.68 years (SD6.31). The mean MMAS scores was 6.11 (SD 1.66) in
which 42.2% were low, 36.4% were medium and only 21.4% were in high adherence
group and the mean HbA1C was 7.94 (SD1.61). Significant association between
medication adherence and different educational level, diabetes duration, medica-
tion number, self monitoring of blood glucose and glycemic control was found.
Higher MMAS score was found in patients with lower HbA1c levels, less number of
medications per day, longer diabetes duration, with self monitoring of blood glu-
cose and higher level of education. MMAS scores correlates significantly with
HbA1c (- 0.505, p 0.001).CONCLUSIONS:The lower HbA1C results in patients with
higher medication adherence can be the result of other factors but this study re-
vealed that adherence is among the modifiable factors that are associated with
better glycemic control. The study results reinforce the recommendation for the
periodic assessment of medication adherence and the use of educational programs
to improve the self-management ability of patients and enhance patients’ aware-
ness about glycemic control with diabetes.
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OBJECTIVES: To describe the clinical and health-related quality of life (HRQoL)
impact of patient-reported mild hypoglycaemic episodes and quantify the extent
of physician-reported agreement with patient-reported mild hypoglycaemic epi-
sodes in patients with type 2 diabetes mellitus (T2DM). METHODS: We have used
data from the Adelphi Diabetes VII (2010) Disease Specific Programme (DSP) which
collected data from 379 Primary Care physicians (PCPs) across 5 EU countries -
France, Germany, Italy, Spain and UK- for patients receiving at least one oral anti-
diabetic with or without insulin. This generated 1145 physician-completed patient
record forms (PRFs) that could be matched directly to patient-completed question-
naires (PSCs). Patients were asked: “How often do you have mild low blood sugar
experiences (those you have treated by eating some fruit, fruit juice or a sweet)”,
while physicians were asked to capture “How often does the patient experience
mild (self treated) hypoglycaemic episodes”? RESULTS: 88 patients out of 1093
(8.05%) reported hypoglycaemic episodes, whereas physicians reported that only
39 patients (3.57%) suffered hypoglycaemic episodes. Physician and patient did not
agree in 55 cases. The Fisher’s test suggests that the physician-reported prevalence
of hypoglycaemic episodes was not influenced by whether or not the patient com-
pleted a PSC (p0.374). Multivariate regression analysis including age, gender, BMI,
and duration of T2DM as covariates shows that the utility decrement (HRQoL) is
-0.0687 (p0.01) between the patients who had experienced hypoglycaemic epi-
sodes and those who had not. Patients who reported hypoglycaemic episodes also
had a significantly higher HbA1c 0.374 (p0.01) than those who did not report
hypoglycaemia. CONCLUSIONS: PCPs in Europe may underestimate the true inci-
dence rate of mild hypoglycaemia as their treated patients report over twice as
many as they do. The occurrence of patient-reported hypoglycaemic episodes is
associated with lower HRQoL and significantly higher HbA1c and hence has sub-
stantial clinical impact.
PDB55
TRANSLATION AND VALIDATION STUDY OF 14-ITEM MICHIGAN DIABETES
KNOWLEDGE TEST (MDKT): THE URDU VERSION
Saleem F1, Hassali MA2, Shafie AA3, Al-Qazaz HK1, Atif M4, Haq N1, Ahmad N1, Asif M5
1Universiti Sains Malaysia (USM), Pinang, Penang, Malaysia, 2Universiti Sains Malaysia,
Minden, Penang, Malaysia, 3Universiti Sains Malaysia (USM), Penang, Penang, Malaysia,
4Universiti Sains Malaysia (USM), Pinang, Malaysia, 5The Islamia University of Bahawalpur,
Bahawalpur, Punjab, Pakistan
OBJECTIVES: This study aimed to translate the Michigan Diabetes Knowledge Test
(MDKT) into Pakistani (Urdu) language, and to examine the psychometric proper-
ties of the Urdu version. METHODS: A standard procedure of “forward-backward”
translation procedure was used to create the Urdu version of the MDKT from the
original English version. A convenience sample of 325 outpatients with type 2
diabetes was approached between June and November 2010. All data were col-
lected from Bolan Medical College Hospital, Quetta, Pakistan. In addition to MDKT,
socio-demographic data of the patients was also collected. Patient medical records
were explored to get clinical and hemoglobin A1c data. For the purpose of test-rest
analysis, Spearman’s rho coefficient was used and data was available from 51
patients. Internal consistency was used as a measurement of reliability using Cron-
bach’s alpha. Known group validity was also measured to ensure the consistency of
the MDKT. RESULTS: By using the recommended scoring methods of MDKT, the
mean SD of MDKT scores was reported as 7.562.98. Cronbach’s alpha value was
0.702 showing good internal consistency. Test-retest reliability value was 0.812 (p
0.001). Significant relationship between MDKT categories and HbA1c categories
(chi-square  20.555; p  0.001) was found for known group validity.
CONCLUSIONS: The findings of this validation study reveal that that the Pakistani
(Urdu) version of the MDKT is a reliable and valid measure of diabetes knowledge
that can be used in clinical and research practice of Pakistani health care system.
A481V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
